Cargando…

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

BACKGROUND: Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia. The drug is generally well tolerated; however, not infrequent side effects are reported, with the major two being bleeding and ibrutinib-related atrial f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reda, Gianluigi, Fattizzo, Bruno, Cassin, Ramona, Mattiello, Veronica, Tonella, Tatiana, Giannarelli, Diana, Massari, Ferdinando, Cortelezzi, Agostino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996546/ https://www.ncbi.nlm.nih.gov/pubmed/29891001 http://dx.doi.org/10.1186/s13045-018-0626-0

Ejemplares similares

Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
por: Reda, Gianluigi, et al.
Publicado: (2022)

The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
por: Noto, Alessandro, et al.
Publicado: (2021)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?
por: Noto, Alessandro, et al.
Publicado: (2023)

Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy Hematology Network (REL)
por: Reda, Gianluigi, et al.
Publicado: (2020)

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib
por: Nakhoda, Shazia, et al.
Publicado: (2023)

How to Manage Atrial Fibrillation Secondary to Ibrutinib
por: Essa, Hani, et al.
Publicado: (2021)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
por: Timofeeva, Natalia, et al.
Publicado: (2021)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

High incidence of atrial fibrillation in patients treated with ibrutinib
por: Baptiste, Florian, et al.
Publicado: (2019)

Ibrutinib-associated atrial fibrillation treatment with catheter ablation
por: Kapoor, Ridhima, et al.
Publicado: (2021)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Davis, Joanne E., et al.
Publicado: (2021)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

5-Methoxytryptophan alleviates atrial structural remodeling in ibrutinib-associated atrial fibrillation
por: Shuai, Wei, et al.
Publicado: (2023)

Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
por: Cortelezzi, Agostino, et al.
Publicado: (2012)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
por: Chowdhury, Subir Roy, et al.
Publicado: (2021)

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients
por: Diamond, Akiva, et al.
Publicado: (2023)

Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience
por: Khalid, Sidra, et al.
Publicado: (2018)

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
por: Stühlinger, Markus C., et al.
Publicado: (2019)

Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications
por: Fracchiolla, Nicola Stefano, et al.
Publicado: (2017)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
por: Caldeira, Daniel, et al.
Publicado: (2019)

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
por: Rendeiro, André F., et al.
Publicado: (2020)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
por: Broccoli, Alessandro, et al.
Publicado: (2021)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
por: Dartigeas, Caroline, et al.
Publicado: (2022)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
por: Brown, Jennifer R., et al.
Publicado: (2017)

Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation
por: Yang, Xinyu, et al.
Publicado: (2020)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_urbaho53ria9u0mc1hkct28b35